Home > Healthcare > Medical Devices > Medical Supplies > U.S. Cancer Contrast Media Market

U.S. Cancer Contrast Media Market Share

Report ID: GMI8339
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

U.S. Cancer Contrast Media Market Share

The U.S. cancer contrast media industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced devices based on different technologies is among a key market strategy.

U.S. Cancer Contrast Media Market Companies

Some of the eminent market participants operating in the U.S. cancer contrast media industry include:

Bayer AG
Bracco Imaging S.p.A.
GE Healthcare Technologies Inc
Guerbet
iMAX Diagnostic Imaging
Lantheus Medical Imaging
nanoPET Pharma GmbH
Subtle Medical, Inc.
Telix Pharmaceuticals Limited
Trivitron Healthcare

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of U.S. cancer contrast media reached USD 2.4 billion in 2023 and is set to witness 4.9% CAGR during 2024 to 2032, propelled by the increasing prevalence of cancer coupled with the growing technological advancements.

The CT scan segment is projected to account for USD 1.2 billion in revenue by 2032, owing to its increasing use for monitoring the response to cancer treatment longitudinally and getting detailed insights into treatment efficacy and progression.

U.S. cancer contrast media industry from breast cancer application segment accounted for 24.1% revenue share in 2023, due to the rising prevalence of breast cancer in the U.S.

Some of the top cancer contrast media companies in the U.S. include Bayer AG, Bracco Imaging S.p.A., GE Healthcare Technologies Inc, Guerbet, iMAX Diagnostic Imaging, Lantheus Medical Imaging, nanoPET Pharma GmbH, Subtle Medical, Inc., Telix Pharmaceuticals Limited, and Trivitron Healthcare.